Pacira Biosciences, Inc. - 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed on January 9, 2014, by Pacira Pharmaceuticals, Inc. (now Pacira Biosciences, Inc.). The filing provides unaudited preliminary revenue estimates for the company's product EXPAREL for the fourth quarter and full year ended December 31, 2013.
Key Financial Metrics
- EXPAREL Q4 2013 Revenue Estimate: Approximately $30.5 million.
- EXPAREL Full Year 2013 Revenue Estimate: Approximately $76.2 million.
- Other Metrics: The filing text does not provide clear values for total company revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes and Outlook
The company indicated that final financial results and additional performance details will be released in late February 2014 alongside the fourth quarter and year-end earnings press release and conference call. No specific material changes versus prior periods were quantified in this preliminary report.
Risks and Contingencies
The filing includes a Safe Harbor statement noting that forward-looking statements regarding expected EXPAREL revenue are subject to risks. Factors that could cause actual results to differ materially include:
- General economic, industry, or political conditions.
- Success of sales and manufacturing efforts for EXPAREL.
- Rate and degree of market acceptance.
- Size and growth of potential markets.
- Commercialization and marketing capabilities.
The company disclaims any obligation to update these forward-looking statements.
Investor Verification Checklist
- Verify the final audited revenue figures for Q4 and full-year 2013 when released in late February 2014.
- Confirm whether the $76.2 million EXPAREL revenue represents the majority of total company revenue or if other product lines contribute significantly.
- Review the upcoming earnings release for details on operating expenses, net income, and cash flow, which are not included in this 8-K.
- Assess the impact of the cited risk factors on the commercialization timeline and market penetration of EXPAREL.